Table 1.

Current portfolio of CFC and procoagulant medications provided by the Brazilian national program on IBDs

CFC/procoagulantTarget patient population
Recombinant factor VIII Hemophilia A 
Plasma-derived factor VIII Hemophilia A 
Plasma-derived factor IX Hemophilia B 
Plasma-derived VWF VWD 
Emicizumab Hemophilia A with inhibitors 
Prothrombin complex concentrate Deficiency of factors II, VII, IX, and X 
Activated prothrombin complex concentrate Hemophilia A with inhibitors 
Recombinant factor VII activated Hemophilia A with inhibitors, factor VII deficiency, Glanzmann thrombasthenia 
Plasma-derived factor XIII Factor XIII deficiency 
Plasma-derived fibrinogen Hypofibrinogenemia and afibrinogenemia 
Desmopressin acetate VWD, mild/moderate hemophilia A 
Tranexamic acid, oral All patients, when indicated 
CFC/procoagulantTarget patient population
Recombinant factor VIII Hemophilia A 
Plasma-derived factor VIII Hemophilia A 
Plasma-derived factor IX Hemophilia B 
Plasma-derived VWF VWD 
Emicizumab Hemophilia A with inhibitors 
Prothrombin complex concentrate Deficiency of factors II, VII, IX, and X 
Activated prothrombin complex concentrate Hemophilia A with inhibitors 
Recombinant factor VII activated Hemophilia A with inhibitors, factor VII deficiency, Glanzmann thrombasthenia 
Plasma-derived factor XIII Factor XIII deficiency 
Plasma-derived fibrinogen Hypofibrinogenemia and afibrinogenemia 
Desmopressin acetate VWD, mild/moderate hemophilia A 
Tranexamic acid, oral All patients, when indicated 

VWF, von Willebrand factor.

or Create an Account

Close Modal
Close Modal